Neurology
Spinal Muscular Atrophy
Expert Roundtables Podcast: Treatment Algorithm and Best Practices in the Management of Spinal Muscular Atrophy
The treatment landscape for spinal muscular atrophy (SMA) has rapidly advanced with multiple US Food and Drug Administration (FDA)–approved therapies, bringing new hope to patients with this disorder. Clinicians must navigate a complex and varied patient population, balancing emerging data (including on combination therapies) with individualized care needs. Listen to today’s podcast for updates on these SMA management–related topics.
Balaji L, Farrar MA, D’Silva AM, Kariyawasam DS. Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective. Expert Rev Neurother. 2023;23(7):571-586. doi:10.1080/14737175.2023.2218549
Brown L, Hoffman K, Corbo-Galli C, et al. Serial casting for contractures in SMA: consensus derived guidelines for treatment. Front Neurol. 2025;16:1502495. Published correction appears in Front Neurol. 2025;16:1646078.
Giess D, Erdos J, Wild C. An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. Eur J Paediatr Neurol. 2024;51:84-92. doi:10.1016/j.ejpn.2024.06.004
Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145-158. doi:10.3233/JND-180304
Schroth MK, Deans J, Bharucha Goebel DX, et al. Spinal muscular atrophy update in best practices: recommendations for treatment considerations. Neurol Clin Pract. 2025;15(1):e200374. doi:10.1212/CPJ.0000000000200374



